A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer

Journal of Experimental Therapeutics and Oncology

Volumn 2, Issue 6, 2002, Pages 325-332

  Marshall, John L ^a   Rizvi, Naiyer ^a   Kauh, John ^a   Dahut, William ^b   Figuera, Manuela ^a   Kang, Min H ^b   Figg, William D ^b   Wainer, Irving ^c   Chaissang, Christoff ^c   Zhaoyang Li, Megan ^d   Hawkins, Michael J ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Depsipeptide; FR901228; Histone deacetylase; Phase I

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CYCLOPEPTIDE; DEPSIPEPTIDE; ENZYME INHIBITOR; FR 901228; HISTONE DEACETYLASE; HEART ENZYME;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; THERAPY; THROMBOCYTOPENIA; ADVANCED CANCER; ANOREXIA; ASTHENIA; CARDIOTOXICITY; CHROMOBACTERIUM; CLINICAL ARTICLE; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; HEART EJECTION FRACTION; HEMATOLOGIC DISEASE; NAUSEA; PRIORITY JOURNAL; SKIN TOXICITY; TUMOR CELL LINE; TUMOR XENOGRAFT; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FATIGUE; FEMALE; HISTONE DEACETYLASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PEPTIDES, CYCLIC; THERAPEUTICS; THROMBOCYTOPENIA;

EID: 18644379905     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2002.01039.x     Document Type: Article

References (11)

1. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47: 301-10, 1994.
2. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126-33, 1998.
3. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 17: 1503-8, 1998.
4. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 58: 1579-83, 1994.
5. Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat 51: 29-38, 1998.
6. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94: 1401-8, 1999.
7. Page JG, Rodman LE, Heath JE, et al. Effect of infusion rate on the toxcity of Depsipeptide (NSC630176). Proc Amer Assoc Cancer Res 36: 368, 1995.
8. Page JG, Rodman LE, Heath JE, et al. Comparison of the toxicity of Depsipeptide (NSC631076) in dogs and rats. Proc Am Assoc Cancer Res 37: 374, 1996.
9. Chassaing C, Marshall JL, Wainer IW. Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases. J Chromatogr B Biomed Sci Appl 719: 169-76, 1998.
10. Li Z, Chan KK. A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics. J Pharm Biomed Anal 22: 33-44, 2000.
11. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228), in patients with refractory neoplsms. Clin Cancer Res 8: 718-28, 2002.